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ABSTRACT
Objective Gluten-free diet (GFD) is the only
management for coeliac disease (CD). Available methods
to assess GFD compliance are insufﬁciently sensitive to
detect occasional dietary transgressions that may cause
gut mucosal damage. We aimed to develop a method to
determine gluten intake and monitor GFD compliance in
patients with CD and to evaluate its correlation with
mucosal damage.
Design Urine samples of 76 healthy subjects and 58
patients with CD subjected to different gluten dietary
conditions were collected. A lateral ﬂow test (LFT) with
the highly sensitive and speciﬁc G12 monoclonal
antibody for the most dominant gluten immunogenic
peptides (GIP) and a LFT reader were used to quantify
GIP in solid-phase extracted urines.
Results GIP were detectable in concentrated urines
from healthy individuals previously subjected to GFD as
early as 4–6 h after single gluten intake, and remained
detectable for 1–2 days. The urine assay revealed
infringement of the GFD in about 50% of the patients.
Analysis of duodenal biopsies revealed that most of
patients with CD (89%) with no villous atrophy had no
detectable GIP in urine, while all patients with
quantiﬁable GIP in urine showed incomplete intestinal
mucosa recovery.
Conclusion GIP are detected in urine after gluten
consumption, enabling a new and non-invasive method
to monitor GFD compliance and transgressions. The
method was sensitive, speciﬁc and simple enough to be
convenient for clinical monitoring of patients with CD as
well as for basic and clinical research applications
including drug development.
Trial registration number NCT02344758.
INTRODUCTION
The mainstay of the management of coeliac disease
(CD) is a strict life-long compliance with gluten-
free diet (GFD).1 2 However, full compliance with
the GFD is very difﬁcult to achieve given the ubi-
quity of gluten as a common food additive, as well
as due to dietary habits, high costs of the GFD and
the social restrictions it imposed on patients.3 At
least one-third of patients with CD do not fully
Signiﬁcance of this study
What is already known on this subject?
▸ Ensuring the compliance of gluten-free diet
(GFD) by patients with coeliac disease (CD)
is a crucial step in the management of CD.
According to several reports, dietary
transgressions are relatively frequent
(36% to 55%).
▸ Available methods to assess GFD compliance
are insufﬁciently sensitive to detect occasional
dietary transgressions that may cause gut
mucosal damage. In addition, these tests only
measure the consequences of dietary
transgressions. There is a need for accurate,
reliable and non-invasive tools to help avoid
the harmful consequences of dietary
indiscretions in CD.
▸ Certain gluten immunogenic peptides (GIP) are
resistant to gastrointestinal digestion and can
interact with the immune system of patients
with CD to trigger an autoimmune response
against transglutaminase and other antigens.
A proportional fraction of the GIP absorbed in
the gastrointestinal tract makes it to the
circulation and is excreted in urine.
What are the new ﬁndings?
▸ In this study, we describe for the ﬁrst time a
non-invasive, novel, speciﬁc and reliable
approach to detect and monitor the presence
of GIP in urine. We have been able to
distinguish gluten consumers from
non-consumers by a quantitative lateral ﬂow
test using anti-α-gliadin monoclonal
antibodies.
▸ GIP were sensitively detected in human urine
samples in positive correlation with the
amount of gluten intake. Our results indicate
that the ingestion of amount as little as
>25 mg of gluten in processed bread (lower
limit of the amount that appears detrimental
for most patients with CD) can be detected in
urine.
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adhere to a GFD.4 5 In addition, 36% to 55% of patients who
declare to fully adhere to a GFD do not achieve histological
remission, probably because of inadvertent lapses in daily gluten
intake.2 5–7
There is no consensus regarding the optimal frequency of
monitoring the GFD or the best tools for assessing compliance.8
Despite the availability of diverse GFD adherence markers, they
have signiﬁcant limitations and are insufﬁciently sensitive to
detect occasional transgressions that may impede full gut
mucosa recovery.9–17 Determination of gluten peptides in faeces
has recently been proposed for direct veriﬁcation of GFD com-
pliance.18 Urine has unique advantages for sampling such as
lower cost, non-invasiveness, easy collection, transport, storage
and relative homogeneity versus faeces.19–21
In this study, we have overcome technical challenges and have
shown the feasibility of measuring gluten immunogenic peptides
(GIP) in urine. These peptides are resistant to gastrointestinal
digestion and account for most of the immunotoxic reactions in
T cells of patients with CD. We assessed compliance with the
GFD in healthy and coeliac individuals by estimation of GIP in
urine with anti-GIP immunochromatographic strips (IC strips).
Notably, the presence of GIP in the urine of patients with CD
correlated with intestinal atrophy. The method appears to be
sensitive, speciﬁc and simple, and should be useful for clinical
monitoring of the GFD in patients with CD and to support
efforts in pharmaceutical coeliac research.
MATERIAL AND METHODS
Study patients
A total of 134 subjects (86 women and 48 men) were randomly
enrolled, of which 58 were patients with CD (age range 3–64
years) and 76 healthy subjects (age range 3–57 years). A total of
69 adults (>16 years of age) and 65 children were included.
Exclusion criteria for all study patients included the presence
of known medical disease, use of prescription medications and
antibiotics in the 2 months prior to the inclusion in the study.
Moreover, healthy patients had no digestive disease symptoms
or family history of CD.
The local ethics committee of the Hospital Virgen de Valme
(Sevilla, Spain) approved the study protocol. Written consent
was obtained from adult patients and, in the case of children,
from parents or legal guardians.
Duodenal mucosa evaluation
In this work, at least four endoscopic biopsies of the distal duo-
denum and two biopsies from the duodenal bulb were pro-
cessed. Duodenal biopsies were ﬁxed in 10% buffered formalin
embedded in parafﬁn and sectioned at 4–5 μm thickness. The
haematoxylin-eosin stained sections were assessed. The study
and quantiﬁcation of intraepithelial lymphocytes (IEL) were per-
formed by immunohistochemistry using automated platform
Leica BOND-III. The proportion and distribution of the IEL
along the glands were determined in all the biopsies. The
mucosal specimens were graded independently according to the
Marsh–Oberhuber’s classiﬁcation.22 23 Biopsies were interpreted
by expert gastrointestinal pathologists (blinded to the clinical
data). We used the cut-off of ≥40 IEL/100 enterocytes for the
Marsh classiﬁcation.
Serology
Serum IgA anti-tissue transglutaminase (TTG) and IgA anti-gliadin
antibodies (AGA) were measured using commercial ELISA
(InmunoCAP Phadia, Uppsala, Sweden). Titres of ≤10 U/mL were
considered negative and those of >10 U/mL were considered
positive.
Urine sampling
All participants were provided sterile containers. Mid-stream
urine samples (50–100 mL) from volunteers were collected and
stored at −20°C until analysis. Urine specimens were mixed by
gentle inversions for at least 30 min before processing.
Urine samples from healthy subjects and patients with CD
were collected under different gluten dietary conditions and
times as follows: (1) to differentiate gluten consumers from
non-consumers, random specimen urines from healthy indivi-
duals (n=10) while following a non-standardised gluten-
containing diet (GCD) and healthy controls on GFD (n=10);
(2) to test the appearance and elimination of ingested gluten in
urine, all excreted urines from healthy subjects (n=13) for
4 days: the ﬁrst 3 days on a GFD and the fourth and last day on
a GCD; (3) to check the detection limit of urinary gluten detec-
tion, all excreted urines from healthy subjects on a GFD (n=4)
after administration of controlled gluten microdoses (25 and
50 mg); (4) to test the sensitivity of gluten measurement in 24 h
total urine, 24 h pooled urine samples from six healthy controls
on GCD and one coeliac patient on GFD and (5) to follow-up
of GFD compliance, random urines from 76 healthy volunteers
(consuming a GCD) and 58 patients with CD on GFD for
>2 years.
Competitive ELISA
A commercial competitive ELISA kit based on G12 monoclonal
antibody (Biomedal, S.L., Spain) was used to analyse the gluten
content of the fragments of wheat white bread administered to
the volunteers in the controlled gluten challenge.
Signiﬁcance of this study
▸ We conﬁrmed the poor correlation of serological tests with
mucosa healing as well as the shortcomings of diet
questionnaires to assess GFD compliance. In contrast, a
good correlation between the presence of GIP in urine and
higher damage in the intestinal epithelium (Marsh II/III
score) was demonstrated.
How might it impact on clinical practice in the
foreseeable future?
▸ The incorporation of this simple immunological assay in
urine could overcome some key unresolved scientiﬁc and
clinical problems in CD monitoring. We identify four main
applications: (1) detection of inadvertent lapses after
appearance of acute symptoms, (2) non-compliance of the
GFD before any anatomic damage, (3) monitoring the
adherence to the treatment in initial period after diagnosis
when patients are less familiar with the diet and (4) the
accurate diagnosis and management of diet in
non-responsive and true refractory CD (RCD) cases.
▸ This technique may also serve to assess the efﬁcacy of new
experimental drugs or strategies to eliminate GIP during
digestion in patients with CD.
▸ It is a signiﬁcant advance that opens up new possibilities
for the gastroenterologist to control the treatment of this
disease, assess GFD compliance and improve the quality of
life of patients with CD.
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Food inquiries
All healthy subjects were instructed to follow speciﬁc dietary
restrictions. GCD was ensured by the ingestion of at least a
portion of pasta, bread or whole grain of cereals like wheat,
barley and rye per day. Adults with CD recorded a collection of
all foods ingested on the 4 days prior to urine sampling. At the
end of the study, compliance with dietary conditions was ascer-
tained through a structured interview.
The dietary history was carefully reviewed by a dietician.
‘Risk products’ were deﬁned as products known to possibly
contain gluten, but for which the exact amount of gluten could
not be calculated due to missing brand information.
Urine peptides concentration
Urine samples were concentrated and cleaned-up using solid-
phase extraction (SPE) technique. SampliQ C18 cartridges
(500 mg, 6 mL) supplied by Agilent (Wilmington, Delaware,
USA) were preconditioned following manufacturer’s recommen-
dations. Separately, a 5 mL mixture of 50% urine in triﬂuoroa-
cetic acid was centrifuged 10 min at 2500 g. The resultant
supernatant was applied to the cartridge and the target com-
pounds were eluted with 1 mL of phosphate-buffered saline for
further use in IC assays.
IC test for detection of GIP
The G12 IC assay was modiﬁed from the guidelines of the
manufacturer (GlutenTox Stick, Biomedal, Sevilla, Spain). After
the SPE of the sample, 100 mL of the blind concentrated were
added into a well (multiwell plate). Then, a G12 IC-strip was
dipped into the well for 30 min and allowed to air-dry after-
wards. The IC strip was introduced into the cassette of a lateral
ﬂow test (LFT) reader and was irradiated with light and the
reﬂection measured.
LFT quantitation
To establish a correlation between GIP content and output
signal of the IC strips, urine from individuals with CD without
gluten peptides was used as control. Individuals with CD were
selected based on its histology and serology. To verify negative
gluten intake of the patients, we conducted a qualitative analysis
by IC strips in concentrated urines as well as in faeces, accord-
ing to the protocol established by Comino et al.18 Different
concentrations of gliadin standard were spiked to control urine
in concentrations ranging from 6.25 to 1000 ng/mL.
GlutenTox Reader (Biomedal, Seville, Spain) was used as
reader for GIP quantiﬁcation in IC strips. Test sticks were
scanned by an optical detector, which continually recorded
measurement data.
Statistical analysis
All results are expressed as mean SD. Each urine sample was
analysed in triplicate. Positive control and buffer blanks were
included in each assay. Statistical analyses were performed with
GraphPad Prism 6 for Windows. Unpaired, two-tailed Student’s
t test was applied and p<0.05 was considered as statistically
signiﬁcant.
We used the non-parametric Fisher’s exact test, Cochran–
Armitage test and Spearman’s correlation coefﬁcient to assess
the presence of GIP in urines of adults with CD and the severity
of Marsh lesion and the estimates of the level of association
between two variables. We used SAS (V.9.4;Cary, North
Carolina, USA) for all statistical calculations. All p values pre-
sented are two-sided.
RESULTS
Detection of GIP in urine
We attempted to determine whether gluten peptides are
excreted and could be detected in urine. Initially, samples were
collected from non-coeliac subjects (n=10) following a GCD,
and IC strips were dipped into samples. No visible signals in
sticks were found in spite of gluten consumption. As gluten pep-
tides were expected to be at very low concentrations in urine,
we decided to perform a SPE to improve the feasibility of GIP
detection. Urines from 20 healthy adults were concentrated and
divided in two groups, one group (n=10) received a non-
standardised diet in which gluten was consumed daily, and
other group (n=10) was subjected to GFD for a week. We
tested the presence of GIP in urines from the individuals
included on the two different diet groups. GIP were detected in
all concentrated urines of subjects on GCD. However, we
detected no GIP in any of the concentrated urines of the volun-
teers on GFD. These results strongly indicated that the signal
was dependent on gluten intake.
Calibration of GlutenTox Reader to quantify the output
signal of urine IC strips
To correlate the GIP concentration and the output signal of
urine IC strips, the LFT analyser GlutenTox Reader was cali-
brated with ﬁve series of gliadin standards. The mean value at
each standard was calculated, as well as its SD and the relative
SD. The calibration function, which ﬁts to a Rodbard function
(data not shown) were calculated and then introduced in the
anti-GIP LFT reader software to quantify the GIP in urines. The
quantiﬁcation limit (QL) of the technique was established as
6.25 ng GIP/mL urine. The uncertainty was 17.6% (5.5–7.35 ng
GIP/mL urine). The limit of technique detection (LDT), deﬁned
as the minimum intensity that the reader is able to detect was
below the lower standard of quantiﬁcation (LDT=42.7–
48.37 mV).
In vivo GIP monitoring of healthy individuals after
consumption of various gluten-controlled diets
To examine the chronology of appearance and elimination of
ingested gluten in urine, a total of 13 healthy volunteers were
subjected to different diet conditions and the collected urines
were analysed by their GIP content by using anti-GIP LFT. We
collected all excreted urines for 1 day in unrestricted conditions
(GCD) from healthy individuals. Then, individuals were submit-
ted to a GFD for 3 days and all excreted urines were collected
until measurable GIP content became undetectable.
Subsequently, a GCD was reintroduced and urines were also
collected. Between three and six different urines per day were
collected. Figure 1A shows an example of representative ana-
lysed IC strips from one healthy subject (aH6). Kinetics of GIP
excretion from four healthy volunteers (aH1, aH5, aH8 and
aH12) revealed that GIP content was undetectable after 16–34 h
from the beginning of the GFD in all tested individuals
(ﬁgure 1B). GIP were detected in urines after 3–9 h of the
reintroduction of dietary gluten. In 12 of 13 healthy individuals
on GFD, the amounts of GIP in urine were below the QL of the
method. The subjects had a good compliance with GFD;
however, a peak of 40 ng GIP/mL urine was detected on the
third day of the trial as shown in the aH12 graph. When
interviewed at the end of the study, that volunteer conﬁrmed
consumption of yogurt with cereals (including wheat) few hours
before the urine collection.
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To test whether the anti-GIP LFTwas capable of detection in
urine, the minimum gluten consumption known to cause histo-
logical abnormalities, two doses of gluten (25 and 50 mg) were
administered to four healthy subjects (ﬁgure 2). One single type
of gluten was used in all cases through a standardised piece of
white bread containing 25 mg gluten. An initial microdose of
Figure 1 Determination of the time to elimination and to appearance of GIP in urines of healthy individuals. Urine samples from healthy
individuals, regularly consuming gluten, who were subject to a GFD were collected until reactive peptides became undetectable. Three to six
different urine samples per day were collected for 4 days. (A) One representative example of the gluten excretion kinetics from the trial with the
representative immunochromatographic strip example of the trial was performed with the samples collected during the study period of one subject.
Blue stripes represent an internal positive control that indicates that the stick worked properly; pink stripes indicate the presence of gluten. (B)
Kinetics of gluten-derived peptides excreted from four healthy volunteers. GIP, gluten immunogenic peptides; GCD, gluten-containing diet; GFD,
gluten-free diet; QL, quantiﬁcation limit; ND, not detectable.
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25 mg gluten was administered and the GIP content was mea-
sured in urine by using anti-GIP LFT. Then, doses of 50 mg
were given and GIP measurements were repeated. GIP became
detectable in urine in all analysed individuals at the 50 mg dose.
Administration of 25 mg gluten resulted in enough GIP in urine
to be visibly detected (over LDT) in three out of four indivi-
duals (aH2, aH4 and aH10) although only in aH2 and aH10
the signal was quantiﬁable (over QL). The signal of aH10 was
clearly over the QL. Therefore, the limit of detection (LD) of
this method could be established as >25 mg of ingested gluten.
The sensitivity of the method in random single urines was
similar to the 24-h urines (data not shown). The measurement
of gluten peptides by collecting 24-h total urine may increase
the chances of detection of ingestion of low amounts of gluten.
Follow-up of GFD compliance in patients with CD with the
anti-GIP lateral ﬂow urine test
The high percentage of patients with CD with insufﬁcient gut
mucosal healing is primarily attributed to inadvertent dietary
lapses and minor voluntary transgressions. Therefore, there is a
need for an accurate marker that would allow short-term moni-
toring of GFD compliance by physicians and patients. To assess
whether the proposed method is suitable for monitoring gluten
ingestion in patients with CD, a study was conducted to
measure GIP in urine of 76 healthy volunteers (42 adults and
34 children) who were consuming a GCD, and 58 patients with
CD (27 adults and 31 children) on long-term GFD (ﬁgure 3).
After consumption of a GCD, all healthy subjects showed gluten
excretion in urine. The range of GIP in urine of healthy subjects
ranged from 6.54 to 604 ng GIP/mL (in adults) and from 6.54
to 369 ng GIP/mL (in children).
The presence of GIP in urine of patients with CD on GFD
revealed the existence of a high percentage of non-compliance
of the GFD. GIP in urine were detectable in 48% of adults and
45% of children. However, GIP content in urine was below the
QL of the method in 70% of adults and 71% of children with
CD. In the remainder individuals with CD, GIP content
ranged from 9.27 to 78.12 ng GIP/mL and from 9.33 to
29.78 ng GIP/mL urine (in adults and children, respectively).
Dietary transgressions in adult patients with CD: correlation
with mucosal damage
To establish a correlation between GIP in urine of adults with
CD and the occurrence of mucosal damage, we conducted a
histological study of 25 intestinal biopsies of adults with CD
who had followed a GFD for at least 2 years (ﬁgure 4).
Only 13 out of the 25 patients were GIP− (52%) and none of
them had histological architectural damage in the mucosa (ie, all
were Marsh 0–I with no Marsh II/III). Of the 13 of the GIP−
individuals, 5 had Marsh 0 (normal mucosa) and 8 had Marsh I
(elevated IEL without architectural changes). All the GIP−
patients were TTG/AGA− as well. Conversely, six out of seven
adults with CD having clear histological abnormalities (Marsh
II-crypt hyperplasia and Marsh III-mucosal atrophy) had detect-
able level of GIP in urine (86%), and only one subject with
Marsh III had detectable but not quantiﬁable amount of GIP in
urine.
Fisher’s exact test showed a signiﬁcant relation (p=0.0007)
between the presence of quantiﬁable GIP (>QL) and severity of
Marsh scale. The strong association was observed to be statistic-
ally signiﬁcant (Cochran-Armitage Trend Test p=0.0005).
Moreover, GIP values showed a signiﬁcant correlation with the
Figure 2 In vivo monitoring of urinary excretion of gluten peptides in healthy individuals on a GFD with consumption of controlled gluten
challenges. Two doses of gluten were administered (25 and 50 mg) to four subjects. Four independent experiments with samples were run in
triplicate. GFD, gluten-free diet; GIP, gluten immunogenic peptides; QL, quantiﬁcation limit; LDT, limit of technique detection; ND, not detectable.
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severity of intestinal mucosa damage (Spearman’s correlation,
r=0.75). As additional supportive investigation, dietary histories
from adults with CD were reviewed. We found that all respon-
ders reported full GFD compliance. Some patients were sus-
pected to have consumed gluten in meals prepared away from
home (eg, Spanish tomato soup, sausages and potato chips).
Because at least one-third of adults with CD showed GIP in
urine >QL, it could be concluded that the collection of dietary
intake did not reﬂect the gluten intake, whether voluntary or
involuntary. Moreover, no correlation was found between
dietary history and mucosal healing.
Unlike the excellent correlation of GIP with histology, sero-
logical data had no correlation with mucosal damage. Positivity
in anti-TTG and/or AGA was found in only four individuals,
two with Marsh I and the other two with Marsh II. Five
patients with severe lesion in mucosa were not positive in either
TTG or AGA (71.4%).
Hence, this study indicated that only urine GIP detection cor-
related with compliance with the GFD and with mucosal
healing in patients with CD on a GFD.
DISCUSSION
In this study, we describe for the ﬁrst time a novel, speciﬁc and
reliable approach to detect and monitor the presence of GIP in
urine by means of G12 IC strips. The recovery of measurable
amounts of gluten peptides in urine indicates that gluten has
been absorbed by the intestinal mucosa, has reached the circula-
tion and has been ﬁltered by the kidney.
To date, available methods to monitor GFD compliance only
measure the consequences of dietary transgressions and many
studies have reported poor effectiveness.24–31 The use of endos-
copies to collect biopsies and assess mucosal healing is the gold
standard; however, it is invasive, expensive and not a practical
method for serial monitoring. Hence, there is a need for accur-
ate, non-invasive tools to help avoid the harmful consequences
of dietary indiscretions in CD.
The resistance of gluten in gastrointestinal digestion ensures
that a signiﬁcant fraction of the ingested gluten is excreted.
A previous report described a new methodology for GFD moni-
toring through the determination of 33-mer equivalent peptidic
epitopes content in faeces.18 However, gluten-containing food
also contains other gluten peptides that present immunogenicity
and they could also be excreted. Methodology based on the
G12 antibody demonstrated its ability to recognise content of
other peptides immunogenic in patients with CD.32 33 Given
the greater convenience of urine over stool collection in some
settings, the herein proposed urine gluten test would become
another useful monitoring tool in clinical practice for follow-up
of the GFD compliance.
IC strips are standard clinical assays in urine in many diseases.
The use of IC strips coupled with an IC reader in urine of
patients with CD could provide a quantitative measurement of
dietary infringement, providing signiﬁcant advantages in the
follow-up of GFD compliance. In this study, we have been able
to distinguish gluten consumers from non-consumers by using
G12 dipsticks in urine. A wide range of gluten peptide amounts
(from 6.54 to 604 ng) could be detected in urine after GCD.
The time of gluten peptide excretion in urine was proved to be
between 1 and 2 days after gluten ingestion, in contrast to
3–4 days in stools.18 Interindividual diversity (weight, sex, age,
gut microbiota, etc), type of gluten-containing food (beer, pasta,
bread, cookies, etc), the daily amount of liquid intake and the
accompanying diet may have a considerable impact on the
resultant GIP concentration and excretion time in urine.
The concept of ‘daily gluten tolerable intake’ has received
special attention and daily gluten consumption >10–50 mg
appears detrimental for many patients with CD.24 34–36 Our
results indicate that the gluten ingestion of >25 mg in processed
bread could be detected in urine.
Figure 3 Detection and quantiﬁcation of GIP in urine samples of
healthy and individuals with CD. Patients with CD (n=58) were on GFD
and healthy individuals (n=76) on GCD. Each point represents the
mean absorbance value of one urine sample from individuals at optical
density of 450 nm. According to the QL of technique, individuals with
a higher or equal GIP value than QL were considered positive (GIP++)
for the presence of GIP, while those with lower GIP content but higher
than LDT were considered positive not quantiﬁable (GIP+) and those
with lower GIP content than LDT were considered negative (GIP−);
*p<0.0001 (unpaired, two-tailed Student’s t test). CD, coeliac disease;
GIP, gluten immunogenic peptides; GFD, gluten-free diet; GCD, gluten
containing diet; QL, quantiﬁcation limit; LDT, limit of technique
detection; ND, not detectable.
Figure 4 Correlation between the presence of GIP in urine and small
bowel histology in adult patients with CD. Histological appearance
determined by the Marsh scale of the severity of mucosal lesion (Marsh
I–III). GIP− (white bar), absence of GIP in urine; GIP+ (grey bar), visual
presence of GIP not quantiﬁable in urine (>LDT <QL); GIP ++ (black
bar), presence of GIP visible and quantiﬁable in urine (>QL). p=0.0007
(Fisher’s exact test). Values are expressed as percentage of patients. CD,
coeliac disease; GIP, gluten immunogenic peptides; LDT, limit of
technique detection; QL, quantiﬁcation limit.
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Since dietary transgressions are relatively frequent in patients
with CD,4 5 37 a method to determine inadvertent lapses or vol-
untary gluten intake is a long-overdue necessity to help patients
with CD manage their lives and avoid the harmful effects of
gluten exposure while on a GFD. In the current study, we
demonstrated the presence of GIP in patients with CD who had
supposedly consumed long-term GFD (45% and 48% in chil-
dren and adults, respectively). These results were consistent
with reports showing that ∼30%–50% of patients with CD on
GFD remain mucosal atrophy. More importantly, our results
indicate that there is a correlation between the absence of GIP
in urine and healing of the gut intestinal epithelium. In addition,
the histological analysis revealed that 100% of the adults with
CD with higher damage in the epithelia (Marsh II/III) had con-
sumed gluten according to the detection of GIP in urine. In con-
trast, our data conﬁrmed the poor correlation of serological
tests with mucosal healing, consistent with other studies,12–14 as
well as the shortcomings of the dietary history questionnaires to
assess GFD compliance.
Refractory CD (RCD) is deﬁned by persistent symptoms and
signs of malabsorption despite gluten exclusion for >12 months
with ongoing intestinal villous atrophy.38–43 As there is no
effective method to determine whether refractory symptoms are
due to hypersensitivity to trace amounts of dietary gluten or to
inadvertent gluten exposure, the methodology proposed in this
work might be a useful way to better diagnose and manage
RCD cases.
In this article, we have described how to monitor gluten
intake by a simple immunological assay in urine, thereby over-
coming some key unresolved scientiﬁc and clinical problems in
CD monitoring. We identify four main applications: (1) the
monitoring of short-term and long-term GFD compliance, (2)
assessment of the efﬁcacy of experimental non-dietary treat-
ments in patients with CD, (3) detection of inadvertent lapses
of daily gluten ingestion and (4) differential diagnosis of RCD
from dietary non-compliance.
Future studies with larger number of patients and samples
will further validate the clinical relevance and the applications
of the detection of recent GFD transgressions in urine for the
optimal management of CD.
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